Activity of the antimicrobial peptide and thanatin analog S-thanatin on clinical isolates of Klebsiella pneumoniae resistant to conventional antibiotics with different structures

Current Microbiology

Volumn 59, Issue 2, 2009, Pages 147-153

  Wu, Guo Qiu ^a   Ding, Jia Xuan ^b   Li, Lin Xian ^b   Wang, Hai Liang ^a   Zhao, Rui ^b   Shen, Zi Long ^b  

^a SOUTHEAST UNIVERSITY   (China)

^b CHINA PHARMACEUTICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM; CEFALOTIN; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFUROXIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; S THANATIN; TETRACYCLINE; TICARCILLIN; TIMENTIN; TOBRAMYCIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CLINICAL EVALUATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SYNTHESIS; IN VITRO STUDY; KINETICS; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; DRUG RESISTANCE, BACTERIAL; DRUG SYNERGISM; HETEROPTERA; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICROBIAL SENSITIVITY TESTS; MICROBIAL VIABILITY; PEPTIDES, CYCLIC;

BACTERIA (MICROORGANISMS); HEXAPODA; KLEBSIELLA PNEUMONIAE; PODISUS MACULIVENTRIS;

EID: 67651149503     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-009-9410-2     Document Type: Article

References (19)

1. E Rubinstein GG Zhanel 2007 Anti-infectives research and development problems, challenges and solutions: the clinical practitioner perspective Lancet Infect Dis 7 69 70
2. SR Lockhart MA Abramson SE Beekman 2007 Antimicrobial resistance among gram-negative bacilli as causes of infections in intensive care unit patients in the United States between 1993 and 2004 J Clin Microbiol 45 3352 3359 (Pubitemid 47585661)
3. P Ylipalosaari TI Ala-Kokko J Laurila 2006 Epidemiology of intensive care unit (ICU)-acquired infections in a 14 month prospective cohort study in a single mixed Scandinavian university hospital ICU Acta Anaesthesiol Scand 50 1192 1197 (Pubitemid 44624297)
4. GG Zhanel M DeCorby N Laing The Canadian Antimicrobial Resistance Alliance (CARA) DJ Hoban 2008 Antimicrobial-resistant pathogens in intensive care units in Canada: Results of the Canadian National Intensive Care Unit (CAN-ICU) Study, 2005-2006 Antimicrob Agents Chemother 52 1430 1437
5. ES Moland ND Hanson JA Black 2006 Prevalence of newer β-lactamases in gram-negative clinical isolates collected in the United States from 2001 to 2002 J Clin Microbiol 44 3318 3324 (Pubitemid 44413771)
6. MR Mulvey E Bryce D Boyd 2004 The Canadian Hospital Epidemiology Committee of the Canadian Nosocomial Infection Surveillance Program, Health Canada. Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella sp. in Canadian hospitals Antimicrob Agents Chemother 48 1204 1214
7. D Landman S Bratu S Kochar 2007 Evolution of antimicrobial resistance among Pseudomonas aeruginosa, Acinetobacter baumannii and Klebsiella pneumoniae in Brooklyn, NY J Antimicrob Chemother 60 1 78 82 (Pubitemid 47073279)
8. P Fehlbaum P Bulet S Chemysh 1996 Structure activity analysis of thanatin, a 21-residue inducible insect defense peptide with sequence homology to frog skin antimicrobial peptides Proc Natl Acad Sci USA 93 1221 1225 (Pubitemid 26052869)
9. GQ Wu LX Li JX Ding 2008 High-level expression and novel purification strategy of recombinant thanatin analog in Escherichia coli Curr Microbiol 57 95 101
10. T Hirsch F Jacobsen HU Steinau 2008 Host defense peptides and the new line of defence against multiresistant infections Protein Pept Lett 15 238 243
11. KA Brogden 2005 Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat Rev Microbiol 3 238 250 (Pubitemid 40298223)
12. A Giuliani G Pirri A Bozzi 2008 Antimicrobial peptides: natural templates for synthetic membrane-active compounds Cell Mol Life Sci 65 2450 2460
13. GQ Wu JX Ding H Li 2008 Effects of cations and pH on antimicrobial activity of TS and S-thanatin against Escherichia coli ATCC25922 and B. subtilis ATCC 21332 Curr Microbiol 57 552 557 (Pubitemid 50280667)
14. National Committee for Clinical Laboratory Standards (2001) Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 5th edn. Approved standard M7-A5. National Committee for Clinical Laboratory Standards, Wayne, PA
15. H Khandelia JH Ipsen OG Mouritsen 2008 The impact of peptides on lipid membranes Biochim Biophys Acta 1778 1528 1536
16. Y Shai A Makovitzky D Avrahami 2006 Host defense peptides and lipopeptides: modes of action and potential candidates for the treatment of bacterial and fungal infections Curr Protein Pept Sci 7 479 486 (Pubitemid 44883925)
17. H Ulvatne LH Vorland 2001 Bactericidal kinetics of β-lactoferricins against Staphylococcus aureus and Escherichia coli Scand J Infect Dis 33 507 511 (Pubitemid 32755343)
18. DA Steinberg MA Hurst CA Fujii 1997 Protegrin-1: a broad spectrum, rapidly microbicidal peptide with in vivo activity Antimicrob Agents Chemother 41 1738 1742 (Pubitemid 27339878)
19. RE Hancock HG Sahl 2006 Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies Nat Biotechnol 24 1551 1557 (Pubitemid 44967479)